Early and Intensive T2D Management:

Program Goals

TECOS Sitagliptin in Patients With T2D and Established CVD

FDA Drug Safety Communication

Guidelines: Initial Combination Therapy Recommendations

Fixed-Dose Combination Therapy Rationale for Use

Dapagliflozin/Saxagliptin Add-On to MET

Combination Therapy With DPP-4 Inhibitors: Meta-Analysis

Combination Therapy With SGLT2 Inhibitors Add-On to MET -- Meta-Analysis

SGLT2 Inhibitor + GLP-1 Receptor Agonist Combo Ongoing Trials

Initial Combination Therapy: CANA + MET XR in Drug-Naïve Patients Study Design

Initial Combination Therapy: CANA + MET XR in Drug-Naïve Patients Mean Change in HbA1c

Initial Combination Therapy: CANA + MET XR in Drug-Naïve Patients Proportion of Patients With HbA1c < 7.0%

Triple Therapy: DAPA Add-on to SAXA Plus MET Study Design

Triple Therapy: DAPA Add-on to SAXA + MET Distribution of HbA1c in Patients at Week 2

Fixed-Dose Combination Potential Benefits

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)